Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to
placebo in lowering fasting triglyceride levels in patients with very high fasting
triglyceride levels ≥ 500 and ≤ 2000 mg/dL.